Blood purification in sepsis

Achim Jörres

doi:10.1186/s13054-018-2286-4

Abstract

Blood purification in sepsis

Highlights

The mortality of patients with severe sepsis and septic shock remains unacceptably high
Developed in Japan in the early 1990s, a first European multicenter pilot trial in 36 surgical patients with severe sepsis or septic shock secondary to intraabdominal infection demonstrated that the treatment is safe and may lead to improvement in renal and cardiac parameters [2]
CytoSorb is a hemoadsorption device containing porous polymeric beads capable of removing cytokines and other middle-molecular weight compounds from blood by size exclusion and surface adsorption. It was recently studied in a multicenter Randomized controlled trial (RCT) in 100 mechanically ventilated patients with severe sepsis or septic shock and acute lung injury or ARDS

Summary

Introduction

The mortality of patients with severe sepsis and septic shock remains unacceptably high. Developed in Japan in the early 1990s, a first European multicenter pilot trial in 36 surgical patients with severe sepsis or septic shock secondary to intraabdominal infection demonstrated that the treatment is safe and may lead to improvement in renal and cardiac parameters [2]. Another multicenter RCT in Italy studied 64 patients with severe sepsis/septic shock from intra-abdominal Gram-negative infections and reported that PMX hemoperfusion significantly improved hemodynamics and organ dysfunction and reduced 28-day

Results

Conclusion